Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

CONTEXT: A portion of patients with chronic myeloid leukaemia (CML) develop resistance to the Bcr-Abl tyrosine kinase inhibitors (TKIs), limiting the clinical applications. Previous results have demonstrated the synergistic effects between cryptotanshinone (CPT) and imatinib on apoptosis of CML cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Rubin, Huang, Yilan, Fang, Yun, Wang, Qirui, Yan, Meixiu, Ge, Yuqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259876/
https://www.ncbi.nlm.nih.gov/pubmed/34214017
http://dx.doi.org/10.1080/13880209.2021.1944224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259876/
https://www.ncbi.nlm.nih.gov/pubmed/34214017
http://dx.doi.org/10.1080/13880209.2021.1944224

Ejemplares similares